Navigation Links
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
Date:3/14/2010

such as hypertension and congestive heart failure, than the average surgical patient as defined by the 2008 Society for Thoracic Surgeons (STS) Database. Patients were selected for treatment with the MitraClip device if they met the criteria for surgical intervention from the 1998/2006 American College of Cardiology (ACC)/ American Heart Association (AHA) Joint Task Force Recommendations regarding therapy for valvular heart disease. Patients had at least moderate-to-severe functional or degenerative mitral regurgitation and were either symptomatic or asymptomatic with evidence of compromised left ventricular function, atrial fibrillation or pulmonary hypertension. The echocardiography core laboratory at the University of California, San Francisco (UCSF) reviewed the trial's echocardiograms based on the American Society of Echocardiography (ASE) criteria for assessment of MR and left ventricular function.

About Mitral Regurgitation

MR is the most common type of heart valve insufficiency in the United States and Europe, affecting millions of people worldwide. MR affects more than 8 million people in the U.S. and Europe. There are more than 600,000 new diagnoses of significant MR each year in the U.S. and Europe; however, only about 20 percent of these patients undergo surgery each year. While many patients are either higher-risk surgical patients or not sick enough for surgery, approximat
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
2. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
3. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
4. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
5. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
6. Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer
7. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
8. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
9. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
10. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
11. European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 ... research and,development program for Plasmin (Human), ... this week at the XXIst International,Society ... in Geneva,Switzerland. The information included new ...
... 2007 /PRNewswire/ -- Inspiration,Biopharmaceuticals today announced the ... new, proprietary forms of,recombinant Factor IX to ... highlighted in an oral presentation and a ... International Society on Thrombosis and,Haemostasis (ISTH) in ...
Cached Medicine Technology:New Information on the Potential of Plasmin Shared at ISTH Congress 2New Information on the Potential of Plasmin Shared at ISTH Congress 3New Information on the Potential of Plasmin Shared at ISTH Congress 4Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... stroke a major issue in analysis of 33 research projects ... 33 studies on drugs known as beta blockers has concluded ... than heart surgery. In fact, using beta blockers for non-coronary ... say. , The researchers who conducted the study -- known ...
... bypass does not cause short-term neurological problems in ... heart defects, according to pediatric researchers. The new ... adverse neurological effects after newborn surgery for more ... for school-aged children who receive surgery for these ...
... WASHINGTON, Nov. 10 A Guide to Implementing,GASB 45, a ... Government,Excellence, examines how North Carolina local governments are meeting their,obligations ... issue brief, which is based on a survey of the ... $100 million, reports that:, -- 88 percent ...
... -- Net Revenue Increased 93.6% to US$146.5 million; Non-GAAP Gross Margins ... ... Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ), ... its selected,unaudited financial results for the third quarter and nine months ...
... (Amex: IMM ) today announced results for its ... three months ended September 30, 2008, revenues were $506,000,as ... 30, 2007.,The decrease was primarily attributable to revenues from ... three months ended,September 30, 2008 was $2,446,000, as compared ...
... leads to more bleeding, longer hospital stay, study finds , , ... the clot-preventing drug Plavix less than five days before having ... more likely to require a second operation, and will spend ... current guidelines. , Those guidelines from the American College of ...
Cached Medicine News:Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3Health News:No drop in IQ seen after bypass for child heart surgery 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 3Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 4Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 5Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 6Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 7Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 8Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 9Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 10Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 11Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 12Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 13Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 14Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 15Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 16Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 17Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 18Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 19Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 20Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 21Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 22Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 23Health News:Immtech Reports Fiscal Second Quarter 2009 Results 2Health News:Immtech Reports Fiscal Second Quarter 2009 Results 3Health News:Study Upholds Stopping Plavix Use Before Surgery 2
... the dynamic way to manage a contracture. ... effective in reducing contractures. Full ROM is ... therapies. Can also be used as a ... and soft tissue contractures. Use where ROM ...
Swedish Knee Cage -- hinged to track knee motion. Effective control of genu recurvatum (back knee or knee hyperextension). Fits left or right....
... designed to stabilize the knee in full ... the knee with cushioned straps, and is ... knee, even at full extension. Because of ... the Knee Immobilizer is ideal for post-op ...
... Unique in the Cryo/Cuff line, the ... cuff is filled directly with water and ... To ensure the optimal amount of compression, ... pressure after application. The cuff remains cold ...
Medicine Products: